Edwards Lifesciences Announces New Data on EVOQUE Tricuspid Valve Replacement System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Should l Buy EW?
Edwards Lifesciences announced new data on the EVOQUE transcatheter tricuspid valve replacement system at the American College of Cardiology Annual Scientific Session, demonstrating significant and sustained patient benefits including lower mortality when accounting for patient crossover, extending the findings presented at the European Society of Cardiology Congress. The new TRISCEND II trial data presented today during a late-breaking featured research session at ACC.26 demonstrated confidence in two-year performance of TTVR with the EVOQUE system and showed: Significant and sustained near elimination of tricuspid regurgitation; Improvements in health status and quality of life; No added device-related risk; and Significantly lower all-cause mortality when accounting for patient crossover. "There is a significant patient population suffering with debilitating symptoms from tricuspid regurgitation with very limited treatment options. It's not a surprise that the sickest patients enrolled in the medical therapy control group of the randomized TRISCEND II trial opted to receive treatment with the EVOQUE system following the one-year primary endpoint, underscoring both the benefits of and need for TTVR therapy," said Vinod Thourani, MD, FACS, FACC, Bernie Marcus Chairman, Department of Cardiovascular Surgery and Marcus Valve Center, Piedmont Heart Institute. "Our analyses, including the many highly symptomatic crossover patients, showed significantly improved outcomes for all of the EVOQUE treated patients." The 18-month data of the TRISCEND II trial were presented at ESC in August 2025, showing achievement of a hard endpoint benefit for the most severe TR patients who received the EVOQUE therapy, and superior quality of life benefits, regardless of baseline TR.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EW
Wall Street analysts forecast EW stock price to rise
24 Analyst Rating
16 Buy
8 Hold
0 Sell
Moderate Buy
Current: 83.500
Low
84.00
Averages
96.52
High
105.00
Current: 83.500
Low
84.00
Averages
96.52
High
105.00
About EW
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Close Higher: S&P 500 Hits All-Time High
- S&P 500 Hits Record High: The S&P 500 index rose by 0.80%, closing at an all-time high, reflecting market optimism about economic recovery, particularly driven by technology stocks, which further solidifies investor confidence.
- Intel's Strong Performance: Intel's stock surged over 23% after forecasting Q2 revenue between $13.8 billion and $14.8 billion, significantly exceeding the $13.04 billion expectation, indicating strong confidence in the semiconductor industry's potential driven by artificial intelligence, which may spark increased investment in the sector.
- Consumer Confidence Rebounds: The University of Michigan's consumer sentiment index was revised upward to 49.8, surpassing the expected 48.5, suggesting an increase in consumer confidence regarding economic prospects, which could drive consumer spending and economic growth.
- International Dynamics Affecting Markets: Progress in US-Iran negotiations has boosted market sentiment; despite tensions in the Strait of Hormuz, optimism about future talks may alleviate energy price pressures and promote stock market gains.
See More
US Stocks Mostly Higher, Intel Hits Record High
- Intel Stock Surge: Intel (INTC) shares rose over 22% to a record high after forecasting Q2 revenue between $13.8 billion and $14.8 billion, significantly exceeding expectations of $13.04 billion, thereby boosting overall confidence in the semiconductor sector and reflecting optimism about the economic potential of artificial intelligence.
- Consumer Confidence Rebound: The University of Michigan's consumer sentiment index was revised upward to 49.8, surpassing expectations of 48.5, indicating an increase in consumer confidence which could stimulate spending and drive economic growth.
- Oil Price Volatility Impacting Markets: WTI crude oil prices fell over 1% amid expectations of renewed US-Iran talks, potentially exacerbating the global energy crisis and affecting operational costs and profit forecasts for energy-intensive sectors.
- Strong Earnings Season Performance: So far, 81% of the 123 S&P 500 companies that reported earnings have beaten estimates, with Q1 earnings projected to climb 12% year-over-year, demonstrating resilience in corporate profitability that may further boost market sentiment.
See More
Mixed US Stocks with Intel Surging 22% on Strong Q2 Forecast
- Intel's Strong Outlook: Intel forecasts Q2 revenue between $13.8 billion and $14.8 billion, exceeding expectations of $13.04 billion, leading to a 22% stock surge that reignites optimism in the semiconductor sector, potentially driving increased investments and R&D across the industry.
- Market Optimism: The stock market is mostly higher as talks between the US and Iran appear to be resuming, with the Nasdaq 100 reaching an all-time high, reflecting investor expectations for reduced geopolitical risks, which may enhance market stability and investor confidence.
- WTI Oil Price Fluctuations: WTI crude oil prices fell over 1% after initially gaining 1% due to the US naval blockade on Iran, which could exacerbate the global energy crisis, impacting oil prices and the profitability of related companies, particularly in the Middle East.
- Earnings Season Performance: So far, 81% of the 123 S&P 500 companies that reported earnings have beaten estimates, with Q1 earnings projected to rise 12% year-over-year, indicating improved corporate profitability that may further drive stock market gains and bolster investor confidence.
See More
Edwards Lifesciences Raises 2026 Guidance Following Strong Q1 Earnings
- Strong Sales Growth: Edwards Lifesciences reported Q1 2026 sales of $1.65 billion, reflecting a 12.7% year-over-year increase, with CEO Zovighian attributing this growth to heightened market demand and the exit of a competitor, while raising full-year sales growth guidance to 9% to 11%.
- TAVR Sales Performance: Q1 global TAVR sales reached $1.2 billion, an 11% increase year-over-year, with the company projecting TAVR sales to hit $4.7 billion to $5.0 billion in 2026, indicating robust market demand and competitive positioning in structural heart therapies.
- Robust Profitability: The adjusted gross profit margin for Q1 was 78.2%, slightly down from 78.7% a year ago, primarily due to dollar depreciation and increased manufacturing costs related to new therapies, with full-year gross margin guidance maintained at 78% to 79%.
- Share Buyback Program: The company has initiated a $500 million accelerated share repurchase agreement, with approximately $2.4 billion in cash and cash equivalents, demonstrating financial strength and confidence in future growth prospects.
See More
Edwards Lifesciences Q1 2026 Results Beat Expectations and Raise Guidance
- Strong Earnings Beat: Edwards Lifesciences reported Q1 2026 revenue of $1.65 billion, exceeding market expectations by $50 million, showcasing robust performance in the transcatheter aortic valve replacement sector.
- Guidance Upgrade: The company raised its full-year revenue guidance to $6.5 billion to $6.9 billion, surpassing the consensus estimate of $6.67 billion, reflecting optimistic expectations for future market demand.
- Adjusted EPS Increase: The midpoint of the adjusted EPS guidance was raised to $2.95 to $3.05 from the previous $2.90 to $3.05, indicating ongoing improvements in profitability.
- Healthy Cash Position: As of the end of Q1 2026, the company reported cash and cash equivalents of approximately $2.4 billion, providing ample financial support for future investments and operations.
See More
Edwards Lifesciences Reports Q1 Profit Growth
- Profit Growth: Edwards Lifesciences reported a first-quarter profit of $380.7 million, or $0.66 per share, marking an increase from last year's $363.6 million and $0.62 per share, indicating strong demand in the cardiac treatment market.
- Adjusted Earnings: Excluding items, the company reported adjusted earnings of $455.2 million, or $0.78 per share, highlighting robust core business performance and enhancing investor confidence in future growth prospects.
- Revenue Increase: The company's revenue rose 16.7% year-over-year to $1.648 billion, up from $1.412 billion last year, reflecting strong market expansion and product demand globally.
- Future Guidance: The company provided next quarter EPS guidance of $0.70 to $0.76 and full-year EPS guidance of $2.95 to $3.05, indicating management's optimistic outlook for future performance, which may attract more investor interest.
See More
US Stocks Close Higher: S&P 500 Hits All-Time High
- S&P 500 Hits Record High: The S&P 500 index rose by 0.80%, closing at an all-time high, reflecting market optimism about economic recovery, particularly driven by technology stocks, which further solidifies investor confidence.
- Intel's Strong Performance: Intel's stock surged over 23% after forecasting Q2 revenue between $13.8 billion and $14.8 billion, significantly exceeding the $13.04 billion expectation, indicating strong confidence in the semiconductor industry's potential driven by artificial intelligence, which may spark increased investment in the sector.
- Consumer Confidence Rebounds: The University of Michigan's consumer sentiment index was revised upward to 49.8, surpassing the expected 48.5, suggesting an increase in consumer confidence regarding economic prospects, which could drive consumer spending and economic growth.
- International Dynamics Affecting Markets: Progress in US-Iran negotiations has boosted market sentiment; despite tensions in the Strait of Hormuz, optimism about future talks may alleviate energy price pressures and promote stock market gains.
See More
US Stocks Mostly Higher, Intel Hits Record High
- Intel Stock Surge: Intel (INTC) shares rose over 22% to a record high after forecasting Q2 revenue between $13.8 billion and $14.8 billion, significantly exceeding expectations of $13.04 billion, thereby boosting overall confidence in the semiconductor sector and reflecting optimism about the economic potential of artificial intelligence.
- Consumer Confidence Rebound: The University of Michigan's consumer sentiment index was revised upward to 49.8, surpassing expectations of 48.5, indicating an increase in consumer confidence which could stimulate spending and drive economic growth.
- Oil Price Volatility Impacting Markets: WTI crude oil prices fell over 1% amid expectations of renewed US-Iran talks, potentially exacerbating the global energy crisis and affecting operational costs and profit forecasts for energy-intensive sectors.
- Strong Earnings Season Performance: So far, 81% of the 123 S&P 500 companies that reported earnings have beaten estimates, with Q1 earnings projected to climb 12% year-over-year, demonstrating resilience in corporate profitability that may further boost market sentiment.
See More
Mixed US Stocks with Intel Surging 22% on Strong Q2 Forecast
- Intel's Strong Outlook: Intel forecasts Q2 revenue between $13.8 billion and $14.8 billion, exceeding expectations of $13.04 billion, leading to a 22% stock surge that reignites optimism in the semiconductor sector, potentially driving increased investments and R&D across the industry.
- Market Optimism: The stock market is mostly higher as talks between the US and Iran appear to be resuming, with the Nasdaq 100 reaching an all-time high, reflecting investor expectations for reduced geopolitical risks, which may enhance market stability and investor confidence.
- WTI Oil Price Fluctuations: WTI crude oil prices fell over 1% after initially gaining 1% due to the US naval blockade on Iran, which could exacerbate the global energy crisis, impacting oil prices and the profitability of related companies, particularly in the Middle East.
- Earnings Season Performance: So far, 81% of the 123 S&P 500 companies that reported earnings have beaten estimates, with Q1 earnings projected to rise 12% year-over-year, indicating improved corporate profitability that may further drive stock market gains and bolster investor confidence.
See More
Edwards Lifesciences Raises 2026 Guidance Following Strong Q1 Earnings
- Strong Sales Growth: Edwards Lifesciences reported Q1 2026 sales of $1.65 billion, reflecting a 12.7% year-over-year increase, with CEO Zovighian attributing this growth to heightened market demand and the exit of a competitor, while raising full-year sales growth guidance to 9% to 11%.
- TAVR Sales Performance: Q1 global TAVR sales reached $1.2 billion, an 11% increase year-over-year, with the company projecting TAVR sales to hit $4.7 billion to $5.0 billion in 2026, indicating robust market demand and competitive positioning in structural heart therapies.
- Robust Profitability: The adjusted gross profit margin for Q1 was 78.2%, slightly down from 78.7% a year ago, primarily due to dollar depreciation and increased manufacturing costs related to new therapies, with full-year gross margin guidance maintained at 78% to 79%.
- Share Buyback Program: The company has initiated a $500 million accelerated share repurchase agreement, with approximately $2.4 billion in cash and cash equivalents, demonstrating financial strength and confidence in future growth prospects.
See More
Edwards Lifesciences Q1 2026 Results Beat Expectations and Raise Guidance
- Strong Earnings Beat: Edwards Lifesciences reported Q1 2026 revenue of $1.65 billion, exceeding market expectations by $50 million, showcasing robust performance in the transcatheter aortic valve replacement sector.
- Guidance Upgrade: The company raised its full-year revenue guidance to $6.5 billion to $6.9 billion, surpassing the consensus estimate of $6.67 billion, reflecting optimistic expectations for future market demand.
- Adjusted EPS Increase: The midpoint of the adjusted EPS guidance was raised to $2.95 to $3.05 from the previous $2.90 to $3.05, indicating ongoing improvements in profitability.
- Healthy Cash Position: As of the end of Q1 2026, the company reported cash and cash equivalents of approximately $2.4 billion, providing ample financial support for future investments and operations.
See More
Edwards Lifesciences Reports Q1 Profit Growth
- Profit Growth: Edwards Lifesciences reported a first-quarter profit of $380.7 million, or $0.66 per share, marking an increase from last year's $363.6 million and $0.62 per share, indicating strong demand in the cardiac treatment market.
- Adjusted Earnings: Excluding items, the company reported adjusted earnings of $455.2 million, or $0.78 per share, highlighting robust core business performance and enhancing investor confidence in future growth prospects.
- Revenue Increase: The company's revenue rose 16.7% year-over-year to $1.648 billion, up from $1.412 billion last year, reflecting strong market expansion and product demand globally.
- Future Guidance: The company provided next quarter EPS guidance of $0.70 to $0.76 and full-year EPS guidance of $2.95 to $3.05, indicating management's optimistic outlook for future performance, which may attract more investor interest.
See More
